Tigermed (泰格医疗) A+H: PHIP Updates and Thoughts on Valuation
Hangzhou Tigermed, a leading China-based CRO company, is seeking a USD 1.5 bn H-share listing in Hong Kong. In our previous note, we discussed that...
458 Views
Tigermed IPO: PHIP Highlights the Trade-Offs
Hangzhou Tigermed Consulting (300347 CH) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...
374 Views
Hepalink Pharma IPO: Trading Debut
Shenzhen HepaLink Pharmaceuticals (H) (HEPALINK HK) is a leading China-based pharmaceutical company with global businesses in pharmaceutical,...
409 Views
Hepalink Pharma IPO: Valuation Insights
Shenzhen HepaLink Pharmaceuticals (H) (HEPALINK HK) is a leading China-based pharmaceutical company with global businesses in pharmaceutical,...
481 Views
Global Equity Strategy: Short-Term Bullish Trends Clash With Longer-Term Resistance
For now we view the recent pullback as a countertrend move that helped correct the extended and overbought conditions we noted over the past two...
383 Views